ASCO 2022: T-DXd in HER2-Low Unresectable and/or Metastatic Breast Cancer
Posted: 06/05/2022 | By: Chase Doyle

Question 1 of 5

In the phase III DESTINY-Breast04 study, patients with hormone receptor (HR)-positive breast cancer who were randomly assigned to receive fam-trastuzumab deruxtecan-nxki (T-DXd) had a median progression-free survival of how many months?

Choose 1